The 14th San Diego Bio-Pharma Conference 2015

Date: 13th Jun, 2015

IMG_8678

Program

Date: June 13th, 2015, 8:00am-5:00pm
Location: Hilton, San Diego/Del Mar
Registration: $30 for early birds (by June 8th), $50 for onsite registration, students and postdocs $10 off (The fees include parking at the hotel, program brochure, continental breakfast, coffee break, and lunch).
Online registration:  https://www.123signup.com/event?id=pgqsh
Organizer: Sino-American Biotechnology & Pharmaceutical Professional Association (SABPA)
Co-Organizer:  Elsevier

 

As one of the nation’s premier innovation centers, San Diego biotech beach in recent years has witnessed mega-deals of mergers and acquisitions, highly successful IPOs, the groundbreakings of multiple state-of-the-art research institutes, and many recent launches of new drugs into the market.  All these achievements are driven by many of the forward thinking leaders of our scientific community with great visions and strong determinations to help tackle the most daunting challenges of our time, and to translate scientific discoveries to clinical utilities to benefit mankind.  Come to meet some of these visionary leaders at our upcoming SABPA Bio-Pharma conference to learn more about the latest breakthroughs in science and new trends in our industry, and to network with your peers.  It is one of the biggest San Diego biotech events that you don’t want to miss.


 

Program


 

8:00 am Exhibition (all day)


 

8:00 am Continental Breakfast & Registration


 

8:45 am Opening Remarks:
Yahu Liu, Ph.D., President, SABPA San Diego
Yi Liu, Ph.D., Chair, San Diego Bio-Pharma Conference


 

9:00 am 2015 San Diego Bio-Pharma Achievement Award
Award Recipient: Peter Schultz, Ph.D., Institute Director, Calibr
Keynote Speech: An Expanding Genetic Code


 

9:45 am Title: Pfizer Oncology: Recent Advances in the Treatment of Breast Cancer and Ovarian Cancers
Bob Abraham, SVP and CSO Pfizer’s Oncology Research Unit


 

10:30 am Coffee Break/Networking


 

11:00 am Title: Studies in Natural Product Synthesis
Phil Baran, Ph.D., Professor, Darlene Shiley Chair in Chemistry, Scripps


 

11:30 am Title: Business Model Innovation: A Critical Aspect of Start-Up Companies
Troy Wilson, CEO Kura Oncology, Avidity NanoMedicines and Wellspring Biosciences


 

12:00 am Luncheon/Vendor Display


 

1:45 pm Afternoon session: Innovation and Entrepreneurship


Session Chairs:
JC Xu, MD/PhD, Director of Biology, Quanticel Pharmaceuticals
Guang Chen, MD/PhD, Janssen Fellow, Scientific Director, Translational Research and Behavioral Pharmacology, J&J


 

1:45 pm Title: Augmented Cognitive Training
Tim Tully, CSO Dart Neuroscience


 

2:15 pm Title: Where Science Intersects with Business – Creating Business Dashboards That Combine Data from Multiple Sources
Neal Katz, MBA, Senior Manager of Solutions Marketing, Elsevier


 

2:45 pm Title: How to Build A Healthcare Company in China
Jimmy Wei, Venture Partner KPCB China


 

3:15 pm Coffee Break


 

3:40 pm Plenary Discussion: Innovations in San Diego


Modulator: Kara Bortone, Head of Company Sourcing for JLABS, Johnson &
Johnson Innovation


Panel Expert:
Mitchell Mutz, President & CSO Amplyx Pharmaceuticals
Jamie Christensen, CSO Mirati Therapeutics
Gary Gao, President & CEO, Med Data Quest, Inc
Scott Struther, CEO Crinetics Pharmaceutics
Allan Camaisa, MBA, CEO Parallel 6


 

4:45 pm Title: The Biotech Funding in China
Wayne Wenbao Li, Ph.D., General Manager, Kunming Biomed International; Investment Director, Morningside Technologies


 

5:00 pm Closing Remarks and i-Watch Raffle
Stephanie Shi, Ph.D., EVP, SABPA San Diego


 


 

Calling for sponsorship! Please contact sponsorship@sabpa.org.

To create a platform for the entrepreneurs and VCs to mingle,  a dinner reception (2015 San Diego Bio-Pharma Conference Reception or 生物医药年会招待晚宴) will be held after the 14th San Diego Bio-Pharma Conference at Hilton, San Diego/Del Mar. The reception will be by-invitation-only. To secure an invitation, scientists, entrepreneurs, and other professionals who have projects and ideas please submit a half-page project summary to cc_sabpa@yahoo.com.

Speaker

Confirmed Speakers, Panelists, Chairs, and Moderators :

  • Peter G. Schultz, Ph.D., Institute Director, Calibr
  • Robert T. Abraham, Ph.D., SVP and CSO Pfizer’s Oncology Research Unit
  • Troy Wilson, Ph.D., J.D., CEO Kura Oncology, Avidity NanoMedicines and Wellspring Biosciences
  • Tim Tully, Ph.D., EVP R&D / Chief Science Office, Dart NeuroScience, LLC
  • Phil Baran, Ph.D., Professor, Darlene Shiley Chair in Chemistry, Scripps
  • Neal Katz, MBA, Senior Manager of Solutions Marketing, Elsevier
  • Jimmy Wei, Ph.D., Venture Partner KPCB China
  • Kara Bortone, Ph.D., Head of Company Sourcing for JLABS, Johnson & Johnson Innovation
  • Mitchell Mutz, Ph.D., President & CSO Amplyx Pharmaceuticals
  • James Christensen, Ph.D., CSO Mirati Therapeutics
  • Yuan Gao, Ph.D., President and CEO of Med Data Quest, Inc
  • Scott Struther, Ph.D., CEO Crinetics Pharmaceutics
  • Wayne Wenbo Li, Ph.D., General Manager, Kunming Biomed International; Investment Director, Morningside Technologies

Peter G. Schultz, Ph.D., Institute Director, Calibr
 1-Peter Schultz_cropped_2015-May-02 Dr. Schultz graduated from Caltech in 1979 and continued there for his doctoral degree in chemistry (1984). He then spent a year at the Massachusetts Institute of Technology before moving to the University of California, Berkeley and the Howard Hughes Medical Institute. He is currently the Scripps Professor of Chemistry at the Scripps Research Institute and President of the California Institute for Biomedical Research.Dr. Schultz has made a number of major contributions to science including the discovery of catalytic antibodies, methodology that for the first time expands the genetic codes of living organisms, and the development and application of combinatorial methods in chemistry, materials science and medicine. He has received numerous awards including the Alan T. Waterman Award, NSF (1988), the Wolf Prize in Chemistry (1994), the Paul Ehrlich Prize (2002), the ACS Cope Award (2006) and the Solvay Prize (2013). He is a member of the National Academy of Sciences, USA (1993) and the Institute of Medicine (1998).   He is active on many editorial and scientific advisory boards and is a founding scientist of eight biotechnology/materials companies and founded and directed the Genomics Institute of the Novartis Research Foundation (1999-2010). [Back to top]


 

Robert T. Abraham, Ph.D., SVP and CSO Pfizer’s Oncology Research Unit
 2-Robert Abraham_cropped_2015-May-02 Robert Abraham received his Ph.D. in Pharmacology from the University of Pittsburgh in 1981. He pursued his postdoctoral training in pharmacology and immunology at the Mayo Clinic, where he rose to the rank of Professor in both of disciplines. From 2001-2005, he served as Founder and Director of the Signal Transduction Program and eventually Director of the Cancer Center at the Sanford-Burnham Institute for Biomedical Research. His most notable research contributions were in the areas of T-cell biology, growth factor receptor signaling, autophagy, and DNA damage recognition and repair. Dr. Abraham left academia in 2005 to lead Oncology Discovery Research at Wyeth, and after the acquisition of Wyeth by Pfizer, he was named Senior Vice President and Chief Scientific Officer of Pfizer’s Oncology Research Unit. [Back to top]


 

Troy Wilson, Ph.D., J.D., CEO Kura Oncology, Avidity NanoMedicines and Wellspring Biosciences
 3-Troy Wilson_cropped_2015-May-02 Troy Wilson serves as President and Chief Executive Officer and as a member of the board of directors of Kura Oncology, Inc. He also serves as President and Chief Executive Officer of Wellspring Biosciences LLC and its parent company Araxes Pharma LLC as well as President and Chief Executive Officer of Avidity NanoMedicines LLC. Previously, Dr. Wilson served as President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc. from its inception until its acquisition by Takeda Pharmaceuticals. He serves as a member of the board of directors of Puma Biotechnology, Inc. and Zosano Pharma, Inc. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry from the University of California, Berkeley. [Back to top]


 

Tim Tully, Ph.D., EVP R&D / Chief Science Office, Dart NeuroScience, LLC
 5-Tim Tully_cropped_2015-May-07 Dr. Tully has studied the genetic basis of memory for his entire career. He discovered that a gene called CREB plays an important role in regulating the conversion of short-term memory to long-term memory. This finding suggested that small molecule modulators of the CREB pathway might enhance memory and, therefore, would be useful in treating memory-related disorders such as Alzheimer’s disease. To that end, Dr. Tully helped to found DNS Therapeutics, Inc. in 1997, where he remains a member of its Board of Directors. In 1987, Dr. Tully became an Assistant Professor at Brandeis University, Waltham, MA and in 1991 joined the staff of Cold Spring Harbor Laboratory as an Associate Professor, became Professor in 1995, The St. Giles Professor of Neuroscience in 2003, Head of the Division of Neurogenetics in 2006 and finally resigned his professorship at CSHL in 2007 to become Chief Science Officer of Dart Neuroscience LLC. He also is an Adjunct Professor at Tsinghua University in Beijing China and at the National Tsing Hua University in Hsin Chu Taiwan. Dr. Tully has published numerous scientific papers and is on the editorial board of several neuroscience journals. He is the recipient of numerous awards and honors for his research.Dr. Tully received B.S.s in Biology and in Psychology from the University of Illinois in 1976 and a Ph.D. in Genetics in 1981. He pursued postdoctoral training in NeuroGenetics at Princeton University and in Molecular Genetics at M.I.T. [Back to top]


 

Phil Baran, Ph.D., Professor, Darlene Shiley Chair in Chemistry, Scripps
 6-Phil Baran_cropped_2015-May-02 Phil Baran received his B.S. in chemistry from NYU in 1997, his Ph.D. at The Scripps Research Institute in 2001, and from 2001-2003 he was an NIH-postdoctoral fellow at Harvard in the laboratory of Nobel Laureate E. J. Corey. His independent career began at Scripps in the summer of 2003 and in 2006 he was promoted to Associate Professor with Tenure. In 2008 he was promoted to Full Professor and in 2009 he was appointed to the Skaggs Institute. He currently holds the Darlene Shiley Chair in Chemistry.Phil’s laboratory is focused on harvesting the innate wisdom of complex natural products through their scalable total synthesis. It is undeniable that a majority of small molecule medicinal agents are natural products or are inspired by natural product scaffolds. Thus, total synthesis greatly contributes to this arena via the procurement of natural products (and analogs) and the creation of new methodologies to enable new bond disconnections. Emphasis is placed on those methods and transformations that can have the greatest impact to those working in the pharmaceutical and agrochemical industry. He is the co-inventor of numerous reagents that have been commercialized and are now widely used, one of which was designated as “Reagent of the Year” in 2014.Dr. Baran has published over 150 scientific articles and has been the recipient of several ACS awards such as the Pure Chemistry (2010), Fresenius (2006), and Nobel Laureate Signature (2003), and several international distinctions such as the Hirata Gold Medal and Mukaiyama Prize (Japan), the RSC award in Synthesis (UK), and the Sackler Prize (Israel). In 2013 he was named a MacArthur Foundation Fellow. He is the recipient of numerous young investigator awards such as the Beckman and Searle scholarships and from industrial sponsors, including: Amgen, AstraZeneca, Bristol-Myers Squibb, DuPont, Eli Lilly, GlaxoSmithKline, Pfizer, and Roche. He has delivered hundreds of lectures around the world and consults for numerous companies such as Bristol-Myers Squibb, DuPont and TEVA, and is a scientific advisory board member for Eisai, Abide, and AsymChem. He serves on the editorial advisory board of Angewandte Chemie and Journal of the American Chemical Society. In 2012 he co-founded Sirenas Marine Discovery and in 2013 he co-authored The Portable Chemist’s Consultant, an interactive book published on the iBooks store along with his graduate class in Heterocyclic Chemistry (viewable for free by anyone on iTunes University). [Back to top]


 

Neal Katz, MBA, Senior Manager of Solutions Marketing, Elsevier
 7-Neal Katz_cropped_2015-June-02 Mr. Neal Katz has many years of experience bringing information technology solutions to market. As Senior Manager of Solutions Marketing at Elsevier, Mr. Katzl has been responsible for assembling information solutions for life science companies, as well as academic and government institutions. He has developed similar solutions and programs at companies like AT&T and Intel.Mr. Katz has a MBA from City University of New York and resides in New Jersey. [Back to top]


 

Jimmy Wei, Ph.D., Venture Partner KPCB China
 8-Jimmy Wei_cropped_2015-May-02 Jimmy Wei joined KPCB China as a Venture Partner in April, 2012. His primary interests are building new companies in the area of life sciences in China. He also serves as general manager of JHL biotech – one of KPCB China’s portfolio companies. Prior to join KPCB, Jimmy was the Senior Vice President and head of business development at Hutchison MediPharma, where he led the effort to set up multiple partnerships with US and European pharmaceutical companies. Before joining Hutchison in 2007, Jimmy was the Deputy General Manager of Burrill China Group, where he managed Burrill’s business activities related to the Greater China region. Prior to Burrill, Jimmy was the Vice President for WI Harper Group to oversee firm’s life sciences investment. He also worked for McKinsey Shanghai office as a management consultant. Prior to the business career, Jimmy has conducted R&D in several leading research organizations, including Duke University Medical Center and the Chinese Academy of Sciences.Jimmy received a Ph.D. in Biochemistry from North Carolina State University. He also holds an M.B.A. from Darden Business School, University of Virginia and a B.S. degree in Biology from Wuhan University. [Back to top]


 

Kara Bortone, Ph.D., Head of Company Sourcing for JLABS, Johnson & Johnson Innovation
9-Kara Bartone_cropped_2015-June-02 As Head of Company Sourcing for JLABS, Kara is actively building a pipeline of prospects and driving licensee companies through diligence, selection, and joining JLABS. Kara coordinates with the J&J Innovation Centers and J&J Development Corporation to build opportunities and grow relationships between JLABS companies and potential strategic partners.
Kara joined Johnson & Johnson through Prescience International, where she was Director of Corporate Ventures, primarily focusing on the JLABS project. Prior to joining Prescience, Kara led the scientific communications and marketing for Belgian-based Galapagos NV at a period when the company grew from 60 to over 800 employees and completed its initial public offering on Euronext. She holds a BS in Chemistry from the University of North Carolina and a PhD in Biochemistry from the University of Texas. [Back to top]


 

Mitchell Mutz, Ph.D., Chief Scientific Officer, Amplyx Pharmaceuticals, Inc.
 10-Mitchell Mutz_cropped_2015-May-17 Dr. Mitchell began his career in drug discovery in 1997 at the Palo Alto Institute for Molecular Medicine. He later worked at Scios, Inc. in Sunnyvale, on a project to discover small molecule therapeutics to treat Alzheimer’s disease. In 2000, he left Scios to start Labcyte, Inc, a company that employs acoustic beam technology to move liquid for drug screening applications. At Labcyte, Mitchell participated in seeking the initial venture financing of the company, raising $5 million within his first five months of employment. He also served as Director of Chemistry and later as Principal Scientist. Labcyte is now profitable, employs over 100 people worldwide, and its screening systems are in use at all ten of the world’s largest pharmaceutical companies.Dr. Mutz co-founded Amplyx Pharmaceuticals with Professor Gerald Crabtree of Stanford University in 2007. Amplyx employs chemical modification to repurpose existing small molecule drugs to improve efficacy and lower toxicity. Finding it difficult to raise money from large v.c. firms for an early stage company, Amplyx instead raised money from angel investors including Life Science Angels, Tech Coast Angels, and Golden Seeds, and more recently from the National Institutes of Health SBIR grant program. Since 2011, Amplyx has been awarded eight NIH SBIR grants and received over $4.5 million in non-dilutive funding. Amplyx operates from within the Janssen Labs incubator, housed within Janssen Pharmaceuticals in San Diego. Mitchell started his Ph.D. in Chemistry at the University of Rochester and completed his thesis work at Princeton University. He has a B.A. in Chemistry from Oberlin College. Mitchell is an inventor on 32 issued US patents. [Back to top]


 

James Christensen, Ph.D., CSO Mirati Therapeutics
 11-James Christensen_cropped_2015-May-07 Dr. Christensen joined Mirati in June 2013 and has responsibilities for Translational Medicine, Companion Diagnostic Strategy, and Drug Discovery Research. Prior to Mirati, he was the Senior Director of Oncology Precision Medicine in the Oncology Research Unit at Pfizer, a group focused on developing strategies toward patient identification, novel combination approaches, and development of biomarker approaches. Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib (Sutent®) research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib (Xalkori®). Dr. Christensen participated as a member of the Pfizer Cancer Research or Oncology Research Unit leadership team from 2005-2013. Prior to 2003, Dr. Christensen was at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team where he was responsible for leadership of c-Met and erbB family preclinical development programs and aspects of research and development for sunitinib. Dr. Christensen initiated his industry experience at Warner Lambert/Parke-Davis with research focus in receptor tyrosine kinase (RTK) biology and RTK pathway biomarker development in the oncology therapeutic area. Dr. Christensen has authored or co-authored over 150 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, New England Journal of Medicine and others. In addition, Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics.Dr. Christensen received his Ph.D. degree focusing in Molecular Pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis. [Back to top]


 

Yuan Gao, Ph.D., President and CEO of Med Data Quest, Inc
12-Yuan Gao_cropped_2015-June-02 Dr. Yuan Gao is President and CEO of Med Data Quest, Inc. based at San Diego, California. He also co-founded Singlera Genomics at La Jolla with Professor Kun Zhang of UCSD Bioengineering last year. Before venturing into startups, Dr. Gao has served on the faculty of Harvard, Virginia Commonwealth University and Johns Hopkins University. He currently still holds adjunct associate professorship of Biomedical Engineering at Johns Hopkins University. Dr. Gao also worked for four years at IBM T.J.Watson Research Center at Yorktown Heights on his Ph.D. dissertation with the computer vision, linguistics and computational biology group before it became the IBM Computational Biology Center, which later kicked off Blue Gene Project. After his Ph.D. Dr. Gao moved to Harvard for a postdoctoral fellowship with Professor George Church to develop next generation sequencing technologies and bioinformatics analysis algorithms.


In 2008, collaborating with Professor Dennis Lo from The Chinese University Hong Kong, they jointly developed the ground breaking next generation sequencing based noninvasive prenatal diagnosis of fetal chromosomal aneuploidy using circulating cell free DNA from pregnant mother’s plasma. This technology was ranked as 2008 top 10 medical breakthrough by Times Magazine and has become the underlying technologies used by many companies. [Back to top]


 

Scott Struthers, Ph.D., CEO Crinetics Pharmaceutics
 13-Scott Struther_cropped_2015-May-07 Dr. R. Scott Struthers is a Founder of Crinetics Pharmaceuticals. Dr. Struthers received his Ph.D. in Physiology and Pharmacology from the University of California, San Diego under the supervision of Professor Wylie Vale. Following his degree, he led contract research efforts at Biosym Technologies developing and applying computational tools for drug discovery. He then cofounded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. From 1998 to 2008 he held a series of positions at Neurocrine Biosciences, most recently as Senior Director and Head, Endocrinology and Metabolism. There he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, that has demonstrated good safety and efficacy in over 40 clinical trials totaling more than 3000 patients including a 6-month, 872-patient recently completed Phase III study. In 2008, he founded Crinetics Pharmaceuticals to focus on discovery and development of drugs targeting neuropeptide receptors for the treatment of endocrine related diseases and cancers. Dr. Struthers is an author of more than 75 scientific publications. [Back to top]


 

Wenbao (Wayne) Li, Ph.D., General Manager, Kunming Biomed International; Investment Director, Morningsight Technologies
 14-Wayne Wenbo Li_cropped_2015-May-02 Dr. Wenbao (Wayne) Li obtained his Master of Science Degree in 1986 from the Research Center of Eco-Environmental Sciences, Chinese Academy of Sciences and Ph.D. in 1995 from Brigham Young University. He did his post-doctoral research at the Haskell Laboratory for Toxicology and Industrial Medicine at DuPont Company where he subsequently worked as a research scientist for about 5 years. Dr. Li has held director and manager level positions at Genelabs, Rigel and Covance Laboratories. He has more than 25 years of experience in biological and chemical sciences, of which over 15 years were dedicated to drug discovery and development. His expertise is in novel drug preclinical development. He has directly participated and supported drug discovery and development projects for licensing out; had successfully negotiated and closed deals with multinational pharmaceutical companies. In 2007 he has relocated back from US to China and joined Morningside Technologies (a private VC firm focusing on healthcare investment) as an investment project manager. Since 2009 he was assigned as the General Manager of Kunming Biomed International (KBI) and Harmonia (Tianjin) Biotechnology Company, jointly. Both KBI and Harmonia are invested by Morningside Technologies to provide preclinical services for healthcare industry, biopharmaceutical industry and research academies. Dr. Li has more than 30 papers published in leading scientific journals and more than 50 presentations on national and international conferences and symposiums. [Back to top]


 

Back to Event Page

 

Confirmed Speakers, Panelists, Chairs, and Moderators :

  • David Kabakoff, Ph.D, Executive Partner, Sofinnova Ventures and Partner, HealthQuest Ventures
  • Alan J Lewis, Ph.D., CEO, Medistem
  • Dale L. Boger, Ph.D., Professor, Department of Chemistry, The Scripps Research Institute
  • Richard A. Heyman, Ph.D., CEO of Seragon Pharmaceuticals
  • Alan Paau, CLP, MBA, Ph.D., Executive Director & Vice Provost for Technology Transfer,
    Cornell University
  • Jonathan Wang, Ph. D, Senior Managing Director, Asia at OrbiMed
  • Mr. Timothy Hoctor, Vice President, Professional Services, Elsevier Life Science Solutions
  • Chrysa Mineo, Senior Vice President, Corporate Development, Receptos
  • Mike Grey, B.S., President and CEO, Lumena Pharmaceuticals, Inc.; Venture Partner, Pappas Ventures
  • Henry Ji, Ph.D., Director, President and CEO of Sorrento Therapeutics, Inc.
  • Xiaobo Wang, Ph.D., Chief Technology Officer and Vice President, ACEA Biosciences, Inc.
  • Wei-Wei Zhang, MD, PhD., Managing Director, Adventin, Inc.
  • Yajun Guo, Ph.D., Director of SMMU Cancer Institute, Shanghai, China, Director of PLA General Hospital Cancer Center, Beijing, China, President of Chinese Engineering Research Center for Antibody Medicine, P.R. China
  • Xian-Ping Lu, Ph.D., CEO & CSO, Shenzhen Chipscreen Biosciences, Ltd.
  • Mr. Jun Ren, Founder, Chairman & CEO, Shanghai NewSummit Biopharma Group Ltd. P.R. China
  • Greg B. Scott, Founder and Chairman, ChinaBio® Group
  • Zhi Yang, Ph.D., Chairman, Managing Partner & Founder, BVCF

Session Chairs:

  • Mingzhu Zhang,, PhD, Vice President, Medicilon
  • Yi Liu, PhD, CSO, Wellspring Biosciences, Inc.
  • Jiangchun Xu, PhD, Director of Biology, Quanticel Pharmaceuticals
  • Wendy Wang, M.S., Founder and Principle Consultant, Boulder International
  • Yahu A. Liu, PhD, Research Investigator I, Genomics Institute of the Novartis Research Foundation
  • Yang Liu, Ph.D., Director of R&D, Sanford-Burnham Medical Research Institute
  • Xiangming Fang, PhD, President and Co-Founder, Denovo Biomarkers
  • Yung-Chih Wang, PhD, MBA, Vice President of Corporate Development, China, HUYA Bioscience
  • Lina Ma, Ph.D., Postdoc, Salk Institute for Biological Studies

 

David Kabakoff, Ph. D, Executive Partner, Sofinnova Ventures and Partner, HealthQuest Ventures.
KabakoffD Dr. Kabakoff joined Sofinnova Ventures in 2007. He has more than 30 years of experience in R&D and executive management roles in venture backed biotech companies. David has been Chairman, President and/or CEO of five companies that have generated over $3B in aggregate exit value on $837M in invested capital. David currently serves as Chairman of Cebix, and is a board member of Intermune (ITMN), and Allylix. He also serves as Board observer at Histogenics and Nucana. He was formerly Chairman of Trius (TSRX), from inception through its sale in 2013 to Cubist for $707 Million, and Chairman of Amplimmune ,from inception to its sale in 2013 to Astra-Zeneca for up to $500 Million. He was formerly an active advisor and board observer to IntelliKine. Prior to joining Sofinnova, David was CEO of Salmedix, which was sold to Cephalon for $200M. David has been active in the San Diego biotech industry since 1983 and has held senior roles at Hybritech, Corvas, Dura, and Spiros including three CEO roles leading to two IPOs and two trade sales. He has participated in raising over $1 Billion for venture backed companies and supervised over a dozen corporate partnerships.David holds a PhD in organic chemistry from Yale. He currently resides in Rancho Santa Fe with his wife, and he enjoys fine wine, travel, and skiing. [Back to top]
Alan J Lewis, Ph.D., CEO of Medistem
LewisAJ Dr. Lewis recently served as CEO at Medistem Inc, a public regenerative medicines company. He is also a Board of Director of Biomarin, Targazyme, Diavacs and HabitID. He previously was President and CEO of Ambit Biosciences, a public biotechnology company. Dr. Lewis also served as CEO of the Juvenile Diabetes Research Foundation( JDRF) and Novocell( Viacyte), a regenerative medicines company focused on diabetes. He was President of the Signal Research Division of Celgene after Celgene acquired Signal Pharmaceuticals where he was CEO. He held a number of positions at Wyeth including VP Research.Dr Lewis received a Ph.D. in pharmacology from the University of Wales in Cardiff and completed a postdoctoral fellowship at Yale. He was awarded an Honorary Fellowship from the University of Wales in Swansea. [Back to top]
Dale L. Boger, Ph.D., Professor, Department of Chemistry, The Scripps Research Institute.
BogerDL Dr. Dale Boger received his B.Sc. in chemistry from the University of Kansas, Lawrence, Kansas (1975, with highest distinction and honors in chemistry) and Ph.D. in chemistry from Harvard University (1980) under the direction of E. J. Corey. He returned to the University of Kansas as a member of the faculty in the Department of Medicinal Chemistry (1979-1985), moved to the Department of Chemistry at Purdue University (1985-1991), and joined the faculty in the newly created Department of Chemistry at The Scripps Research Institute (1991-present) as the Richard and Alice Cramer Professor of Chemistry. Since 2012, he has served as the Chairman for the Department of Chemistry. Professor Boger is internationally recognized for his work in organic synthesis, heterocyclic chemistry, natural products total synthesis and biological evaluation, synthetic methodology development, and medicinal chemistry, and has made seminal contributions to the understanding of DNA-drug interactions of naturally occurring antitumor-antibiotics. Dr. Bogger received numerous honors and awards including as elected member to US National Academy of Sciences. [Back to top]
Richard A. Heyman, Ph.D., CEO of Seragon Pharmaceuticals
HeymanRA Dr. Heyman, currently serves as CEO of Seragon Pharmaceuticals, a biotech company recently spun-out of Aragon Pharmaceuticals that focuses on the development of Selective Estrogen Receptor Degraders (SERDs) targeting hormone dependent cancers. He was cofounder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in August 2013 for $650 million in cash upfront along with $350 million in contingent development milestones. Previously, he cofounded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases, which was acquired by Exelixis in 2004. Prior to X-Ceptor, he held various roles at Ligand Pharmaceuticals, including Vice President of Research, where he served as project leader leading to the successful identification and development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., and The Jenna Druck Center, a non-profit in San Diego. He is also a member of the Therapeutic Advisory Board for aTyr Pharma and serves on the Executive Committee of the UCSD Moores Cancer Center. He was an NIH postdoctoral fellow and staff scientist at the Salk Institute, working with Dr. Ronald Evans.Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut. [Back to top]
Alan Paau, CLP, MBA, Ph.D., Executive Director & Vice Provost for Technology Transfer, Cornell University
PaauA Dr. Paau currently heads the technology transfer program at Cornell University. Prior to joining Cornell in January 2007, Dr. Paau was Director and Assistant Vice Chancellor for Technology Transfer & Intellectual Property Services at UCSD for nine years. From 1994 to 1998, he was Executive Director of the Iowa State University Research Foundation, Inc. and Director of Intellectual Property & Technology Transfer at Iowa State University. Until 1994, he was Associate Director of the Biotechnology Center at the Ohio State University.Before returning to the academic environment in 1992, Dr. Paau held various research and management positions of increasing responsibilities in the Cetus Corporation and the W.R. Grace & Co. organizations for 12 years and led the development of two commercial products.Dr. Paau holds a Ph.D. degree in Biological Sciences and a Master of Business Administration degree. He also attended the Drake University School of Law. Dr. Paau has supervised the completion of over 1,600 technology license transactions with more than 140 new businesses founded from the licensing of such technologies. [Back to top]
Jonathan Wang, Ph.D., Senior Managing Director, Asia at OrbiMed
WangJ Dr. Wang is a Senior Managing Director, Asia at OrbiMed. With over 20 years of healthcare and life sciences experience, spanning investment, finance and research, he has co-founded OrbiMed Asia. Previously, he was a Partner at Legend Capital and General Manager, Greater China at Burrill & Company. He also worked for WI Harper Group, where he was a Managing Director overseeing the firm’s life sciences activities worldwide, and Walden International. He was a Board Director at ForteBio, Inc. (acquired by Pall Corporation) and is Chairman at Bonovo Orthopedics, Inc. He is a Board Director at EA, Inc. (formerly Chairman), Response Biomedical Corporation (TSE: RBM) and Waterstone Pharmaceuticals, Inc. He is a co-founder and former Chairman of The BayHelix Group, a premier organization of Chinese life sciences business leaders.Dr. Wang holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University. [Back to top]
Mr. Timothy Hoctor, Vice President, Professional Services, Elsevier Life Science Solutions
HoctorT Mr. Hoctor has been with Elsevier Life Science group for 16 years and is responsible for the life science professional services team of scientific and semantic domain experts. The professional services consulting organization defines and oversees collaborative projects with leading global pharmaceutical companies and research groups. Prior to his current role, Tim has held a number of technical and management roles at Elsevier, responsible for development of commercial products in discovery pharmacology and chemistry informatics. Before joining Elsevier from MDL Information Systems, Tim held technical positions at Oracle and Sun Microsystems.Mr. Hoctor holds a B.S. from the University of Southern California and has completed graduate programs in technology and management from Stanford University and MIT. [Back to top]
Chrysa Mineo, Senior Vice President, Corporate Development, Receptos
MineoC Ms. Mineo serves as Senior Vice President, Corporate Development for Receptos and is responsible for the Company’s collaborations with AbbVie, Ono, Lilly, and Janssen Pharmaceuticals. She also played a key role in the Series A and B financing for Receptos, and in the transition of Receptos from a private venture-backed company to a successful IPO candidate in 2013. Ms. Mineo has 24 years of experience in the biotechnology industry, including in roles of increasing responsibility from 1997 to 2009 leading to Senior Director of Business Development for Neurocrine Biosciences. Ms. Mineo led or played a primary role in negotiating and closing more than 28 licensing transactions, 11 of which were product candidate out-licensing deals, eight of which were in clinical development from Phase 1 to registration. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. She began her career in 1987 with Amgen as a member of a cellular biology team investigating the therapeutic role of Neupogen®.Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and received her M.B.A. from Duke University’s Fuqua School of Business. [Back to top]
Mike Grey, B.S., President and CEO, Lumena Pharmaceuticals, Inc.; Venture Partner, Pappas Ventures
GreyM Mr. Mike Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc., which recently announced that it was merging with Shire plc, and is a venture partner at Pappas Ventures. Mike has nearly 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of Auspex Pharmaceuticals, Inc., president and chief executive officer of SGX Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2008, president and chief executive officer of Trega Biosciences, Inc., which was acquired by Lion Bioscience in 2001, and president of BioChem Therapeutic Inc. For approximately 20 years, Mike served in various roles with Glaxo, Inc. and Glaxo Holdings, P.L.C., culminating in his position as vice president, corporate development and director of international licensing. Mike also serves on the board of directors of BioMarin Pharmaceutical Inc., Horizon Pharma, Inc. and Selventa, Inc.He received a B.S. in Chemistry from the University of Nottingham in the United Kingdom. [Back to top]
Henry Ji, Ph.D., Director, President and CEO of Sorrento Therapeutics, Inc.
JiH Dr. Ji co-founded and has served as a director of Sorrento Therapeutics, Inc. since January 2006, and as its CEO and President since September 2012. Dr. Ji served as Sorrento’s CSO from November 2008 to September 2012, and as its Interim CEO from April 2011 to September 2012.In 2002, Dr. Ji founded and was President of BioVintage, a biopharmaceutical company. From 2001 to 2002, Dr. Ji served as VP of CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and CEO from its founding until 1999.Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. [Back to top]
Xiaobo Wang, Ph.D., Chief Technology Officer and Vice President, ACEA Biosciences, Inc.
WangXB Dr. Wang received his B.Sc. in telecommunication and information technology from Xidian University, Xi’an, China in 1983 and conducted his Ph.D. and post-doctoral work in biophysical sensor development in University of Wales, UK between 1987 and 1992. Dr. Wang joined University of Texas MD Anderson Cancer Center as a Research Associate in 1993 and became a faculty as an Assistant Professor in 1996. His work mainly focused on the development of biochips and biosensors for biophysical analysis and processing of biological cells in bioMEMS and microfluidic systems. His research work received multiple million dollars funding from US federal and state government agencies such as DARPA, NIH and Texas ATP programs.Dr. Wang joined AVIVA Biosciences as a Senior Director of R&D in 1999, and co-founded ACEA Biosciences in 2002 and is now the Chief Technology Officer and Vice President of ACEA. In his over 10 year’s industrial endeavor, Dr. Wang developed the break-through ion-channel chip technology for high throughput patch-clamp recording and innovative electronic sensor platform for label-free, real-time cell-based assays. Dr. Wang has published more than 60 research papers and has over 30 issued US patents in various areas of biosensors and biochip applications. [Back to top]
Wei-Wei Zhang, M.D., Ph.D., Managing Director, Adventin, Inc.
ZhangWW Since 2006, Dr. Zhang has been pursuing translational medicine, technology transfer from US to China, and leading the projects of development and organizing enterprise investment funds to support the new venture or joint venture development in China. He has founded, co-founded, and led operations for more than eight biotechnology companies and established two corporate and academic R&D units. Some his accomplishment highlights are:

  • Invented and developed the world first Cancer Gene Therapy product (Adp53);
  • Participated in raising the $50M initial funding for Introgen Therapeutics;
  • Founded Shenzhen SiBiono GeneTech Co and raised $8 million equivalent RMB;
  • Invented and developed MiniAdFVIII in GenStar Rx, going public in AMEX, resulted in corporate value increase 100 times from $6 to $600M;
  • Invented and developed IgY Seppro®, obtained over $20 M contracts and sales;
  • Participated in developing a RMB VC/PE fund in China (total committed $300M).

Dr. Zhang was Assistant Professor in MD Anderson Cancer Center. He performed his postdoctoral research at Baylor College of Medicine. Dr. Zhang published more than 60 peer-reviewed articles and was invited present at numerous national and international bio conferences. Dr. Zhang hold M.D. from Zhejiang Medical University in China, Ph. D. from University of Alabama. [Back to top]

Yajun Guo, Director of SMMU Cancer Institute, Shanghai; Director of PLA General Hospital Cancer Center, Beijing; President of Chinese Engineering Research Center for Antibody Medicine, P.R. China
GuoYJ Dr. Yajun Guo completed his M.D. and Ph.D from TMMU and SMMU in China and postdoctoral studies from Harvard Medical School. Dr. Yajun Guo has received many honor and awards. In 1996, Dr. Yajun Guo became a professor in Sidney Kimmel Cancer Center in San Diego and relocated his laboratory to Eppley Cancer Research Institute of Nebraska University Medical Center at Omaha in 2000. Starting from 1994, Dr. Yajun Guo established the Shanghai Tumor Immunology and Gene Therapy Center as an international research program and in 1999. He enlarged the center into the present International Joint Cancer Institute. From 2009, he has been working as a director of PLA general hospital cancer center. He is a distinguished professor and director at Shanghai International Joint Cancer Institute, PLA General Hospital Cancer Center and Chinese National Engineering Research Center for Antibody Medicine. He is also a PI of the National Key Basic Research Program Project“Structure and Function of Antibody” and is conducting Seven clinical trials of therapeutic antibodies in China. Currently, Dr. Yajun Guo has several visiting professorships in USA, UK and Australia. [Back to top]
Xian-Ping Lu, Ph.D., CEO & CSO, Shenzhen Chipscreen Biosciences, Ltd.
LuXP Dr. Lu founded Chipscreen Biosciences, the leading drug R&D company in China focusing on innovative small molecular therapeutics, 13 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D (subsidiary of L’Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals.With over 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 60 peer-reviewed papers in prestigious journals including Nature and Science. He is the lead inventor of over 60 patented inventions in areas of small molecule therapeutics.Dr. Lu came to the US in 1989 for postgraduate fellowship at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University. [Back to top]
Jun Ren, Founder, Chairman & CEO, Shanghai NewSummit Biopharma Group Ltd. P.R. China
RenJ In 2001, Mr. Ren founded Shanghai NewSummit Biopharma Group Co., Ltd., a new drug development process solutions provider. Mr. Ren was General Manager of Shanghai Industrial Medical University Biotechnology Co., a subsidiary of Shanghai Fosun Industrial Co., Ltd. (publicly listed). Mr. Ren has over 25 years of managerial experience in medical industry R&D, new drug registration, manufacturing and capital operation, and solid technical background in new drug R&D. He also has rich expertise in integrating resources for new drug registration, clinical trials, and industrialization. Mr. Ren has won numerous awards in China, including the Government Special Subsidy, Second Prize of National Science & Technology Advancement, First Prize of Science & Technology Achievement Award from the Ministry of Health, etc.Mr. Ren also plays key roles on the China Medical Biotechnology Association Quality Control Professionals Committee, China Medical Biotechnology Association BioProduct Professionals Committee, Shanghai Biopharmaceutical Industry Council and Shanghai Biotechnology Association, etc.Mr. Ren obtained his EMBA from CEIBS and MD from Fudan University. [Back to top]
Greg B. Scott, Founder and Chairman, ChinaBio® Group
ScottGB Mr. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® Consulting works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. In 2014, Greg launched ChinaBio® Ventures with Daan Gene and Foshan City to invest in companies bringing western products and technology to China. ChinaBio® Events has organized over 30 conferences focused on investment and partnering, including the highly successful ChinaBio® Partnering Forum which draws over 800 attendees from around the world to China each spring. Greg is also co-founder of two angel investment groups that have funded over 45 biotechnology and medical device companies in the U.S. and China, and Executive Editor of ChinaBio® Today, the most widely read source for China life science news. Greg lives and works in Shanghai but visits San Diego several times a year to enjoy the blue skies and sandy beaches. [Back to top]
Zhi Yang, Ph.D., Chairman, Managing Partner & Founder, BVCF
YangZ Dr. Yang founded BVCF in 2005. He has over 16 years of China and U.S. life sciences investment experience, with a total of over 20 years in the life sciences industry as a private equity investor, venture capital investor, senior executive, entrepreneur, and scientific inventor. As private equity and venture capital investor, he has built portfolios of 25 companies, with 8 exits (4 IPO, 4 acquisitions). As entrepreneur, he co-founded 7 companies, 6 of which continue to conduct business and grow. As scientist, he was the principal inventor of more than 10 U.S. and international patents, which have been documented to have earned MNC’s over $250 million. He was a senior fellow and faculty member at Rockefeller University and is now an advisor to the China Health and Medical Development Foundation, under China’s Ministry of Health.Dr. Yang earned his Ph.D. in Molecular Biology and Biochemistry at Harvard University as a fellow of CUSBEA’s first class, the first group of mainland Chinese biology scholars selected to be brought to the U.S. after China opened its doors in 1979. [Back to top]
Mingzhu Zhang, Ph.D., Vice President, Medicilon
ZhangM Dr. Mingzhu Zhang is the VP of business development and head of US BD at Shanghai Medicilon, one of the leading preclinical CROs in China. In the past 7 years, Dr. Zhang has built strong network with US pharmaceuticals, Chinese pharmaceuticals and CROs, introduced business from more than 50 US biotech/pharmaceutical companies to Chinese CROs, facilitated several licensing deals between US biotech and China pharmaceutical companies and coordinated the collaboration.Dr. Zhang is the president of SABPA San Diego and vice chair of the board of director of SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association), a non-profit organization based in San Diego. She has served at SABPA for 7 years as chair of Fund-raising committee (2006-2010), Chair of China Connection Committee (2010-2011), executive VP of SABPA (2011-2012). She also served as the chair of career development committee at the ACS (American Chemical Society) San Diego Section (2008-2009), and VP of Membership and Sponsorship of ACCEF (American Chinese Culture and Education Foundation) (2004-2006).Dr. Zhang holds a Ph.D. degree in organic chemistry from Shanghai Institute of Organic Chemistry (SIOC) and was a post-doctoral fellow in the Scripps Research Institute (TSRI) and then Vanderbilt University. Dr. Zhang has 7 years experience in business development, 8 years experience in pharmaceutical industry including DuPont Pharmaceuticals and Neurocrine Biosciences. [Back to top]
Yi Liu, Ph.D., CSO, Wellspring Biosciences, Inc.
LiuY Dr. Liu currently serves as CSO of Wellspring Biosciences, a biotech company he co-founded that focuses on the discovery and development of small molecule drugs for the treatment of cancer. Dr. Liu was a co-founder and Vice President of Intellikine. The company advanced three drug candidates into clinical trials in four years before it was acquired by Takeda in 2012 for a total of $310M. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation (GNF). Previously, he held research roles at both SGX Pharmaceuticals and Curagen. Dr. Liu is passionate in drug discovery and development and has a proven record of delivering high quality clinical candidates for the treatment of cancer. He has extensive experience and leadership roles in structure-based design, cancer biology, translational research and clinical biomarker application. He is a co-inventor of more than 40 patents and patent applications and co-author of more than 40 scientific publications.Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his M.S. in Computational Chemistry from Beijing University and his B.Eng. in Chemical Engineering from Tsinghua University. [Back to top]
Jiangchun Xu, PhD, Director of Biology, Quanticel Pharmaceuticals
XuJ Dr. JC Xu is Director of Biology, Quanticel Pharmaceuticals. She has more than 15 years of experience in oncology drug discovery and development. Before joining Quanticel, Dr. Xu was with Pfizer for three and a half years and led the cancer genomics projects in the Pfizer Asia Disease group within the Oncology Research Unit. Prior to joining Pfizer, she was Principal Scientist of Oncology Therapeutic Area at Amgen where she led a number of cancer drug discovery programs in hematological cancers. Before joining Amgen, Dr. Xu was Group Leader at Corixa Corporation leading a number of tumor antigen discovery programs utilizing multiple cancer omics approaches. At Corixa, Dr. Xu’s team discovered P504S or AMACR, a diagnostic marker for prostate cancer that is being widely used
in clinical practice for prostate cancer diagnosis. Dr. Xu received her MD degree from Beijing Medical University, now Peking University Health Science Center and her PhD in Immunology from University of Alabama at Birmingham. She had her post-doc training at DNAX Research Institute with Dr. Kevin Moore performing research on IL-10 and IL-10R. She is an inventor of 46 issued patents and 57 pending patents and published more than 40 articles in the peer-reviewed journals.[Back to top]
Wendy Wang,, M.S., Founder and Principle Consultant, Boulder International
WangW Ms. Wendy Wang is the Sr Validation Engineer at Genoptix. Previously, Wendy worked at Pfizer as a Q&C site lead for La Jolla Site Business Technology Service. Wendy has over 15 years integrated experiences in Quality System, Regulatory Compliance (GxPs), Auditing/Vendor Management, Information Security, Project Management, Record Management, and Business Protection. Specifically, she is a Subject Matter Expert in Computer Validation and Compliance, and has been actively involved as a key author in creating V&V guidance document for IT professionals in Life Science industry. Before joining
Pfizer, she held various scientific and engineering positions in biotech company and research/engineering organizations (Agouron, University of California, Riverside, Pharmacy School of The Ohio State University, and R&D Center of Chinese Aerospace Department). Wendy holds a BS in Chemistry from Sichuan University and a MS in Chemistry from New Mexico Tech. Additionally She holds numerous professional certifications in the area of Quality, Auditing, Organization Excellence and Continuous Improvement (CQA, CSQE, CQOE, Six-Sigma).[Back to top]
Yahu A. Liu, Ph.D.,Research Investigator I, Genomics Institute of the Novartis Research Foundation
Yahu Dr. Yahu A. Liu is a research investigator at Genomics Institute of the Novartis Research Foundation, and also serves as Executive VP and a member of BOD in Sino-American Biotechnology and Pharmaceutical Professional Association (SABPA). He previously worked in medicinal chemistry teams at ChemBridge (San Diego, CA), Vertex (San Diego, CA), and Pfizer (Kalamazoo, MI). Prior to coming to the states, he had worked as an associate director in the Chinese Institute of Standards and Technology, CTO of Huarui Fine Chemical Co. Ltd. and a Certificate Engineer (Organic Process Chemistry) at WH Chemical Co. (Beijing, China). In drug discovery research, Yahu is a co-inventor of a couple of preclinical candidates (GTx-134 and 186). His main contribution to organic chemistry includes his discovery of three rearrangement reactions and synthesis of two natural products. He has been a co-editor of two books, an issue editor of two journals, a co-organizer of more than 20 conferences/symposiums and an ad hoc reviewer for 10 scientific journals. Yahu has co-authored more than 100 scientific research papers, invited reviews, granted patents, published patent applications, and US national/international meeting presentations, which have been cited for ~700 times. He received SABPA Outstanding Leadership Award in 2011, SABPA Achievement Award in 2008 and SBTSC Scientific and Technical Achievement award twice.
Yahu received his Ph.D. degree from Case Western Reserve University (Cleveland, OH) in the laboratory of the late Professor Lawrence M. Sayre (Chemistry/Pathology/Environmental Health Sciences). He earned a degree of Master of Engineering from Beijing Institute of Light Industry and obtained his early chemistry education at Shanxi Teacher’s College (China).[Back to top]
Yang Liu, Ph.D., Director of R&D, Sanford-Burnham Medical Research Institute
LiuYang Dr. Yang Liu has eight years of experience in the bioscience reagent field. In early 2003, Dr. Liu first joined Genome Biosciences, Inc, a company that provided genetic modified mouse services. Soon, the company was merged with Chemicon and Dr. Liu started to lead the New Technology Evaluation team at Chemicon, which was acquired by Serologicals in 2003 and then by Millipore in 2006. In 2008 Dr. Liu joined Stemgent, a specialized stem cell reagent company and has been the R&D director since then.Dr. Liu earned his Ph.D. in Developmental and Molecular Biology from Albert Einstein College of Medicine at New York, and had the postdoc training at University of California at San Diego. [Back to top]
Xiangming Fang, PhD, President and Co-Founder, Denovo Biomarkers
xiangming Dr. Xiangming Fang is president and co-founder of Denovo Biomarkers, a biotech startup founded in 2011, specialized in biomarker discovery and personalized medicine. Xiangming Fang has 27 years of experience in biomedical research and product development, including 21 years of biotech industry experience and 15 years of management experience. She was also involved in several startup companies with hands on experience for team building and operation. Previously as the Senior Vice President and Chief Scientific Officer at GenWay Biotech, she is responsible for new technology and product development and production, as well as customer support and partnership coordination. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as the Director of the Cancer Program and the Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development. Dr. Fang’s earlier experiences include gene therapy product development for hemophilia at Baxter Healthcare and GeneMedicine Inc. Dr. Fang obtained her Medical Degree at Zhejiang University Medical School and PhD in Molecular Biology at the University of Alabama. She completed her postdoctoral studies at the University of Texas, MD Anderson Cancer Center. Dr. Fang was the President (2009-2010) of SABPA, San Diego chapter, and current Chair of BOD. [Back to top]
Yung-Chih Wang, PhD, MBA, Vice President of Corporate Development, China, HUYA Bioscience
WangYC Dr. Yung-Chih Wang is VP of Corporate Development-China at HUYA Bioscience, a U.S.-headquartered company collaborating with Chinese innovators to develop novel therapeutics from China for global markets.Dr. Wang’s main responsibilities include optimal planning and execution of strategies to build HUYA’s team and collaborative networks in China for achieving the corporate goals.has over 15 years of industry experience in pharmaceutical R&D, alliance establishment and business development, plus16 years’ academic research experience in biochemistry and molecular biology. Before joining HUYA in 2010, she was Senior Scientist at Ferring Pharmaceuticals, where she led projects in drug target identification and validation, drug screening and characterization.She also established and managed collaborations with external groups, formed and implemented strategic plans for drug discovery programs, and synthesized knowledge from scientific and business data for management decision-making.Dr. Wang has been an active SABPA member since 2007 and formerly served as Chair of the Pacific Forum 2011-2013. She received her Ph.D. in Biochemistry from the University of Iowa, postdoctoral training at Cold Spring Harbor Laboratory, and MBA from the Rady School of Management at University of California, San Diego.She also received her M.S. in Biochemistry and B.Sc. in Botany from National Taiwan University. [Back to top]
Lina Ma, Ph.D, Postdoc, Salk Institute for Biological Studies
MaLN Dr. Lina Ma is a Postdoc in the Salk Institute for Biological Studies. She has been working on the genetic basis of certain respiratory disease and using integrated approach to identify the pathogenic mutations and characterize the molecular mechanism for this congenital disease. Dr. Ma has an extensive experience and broad knowledge of molecular biology, genetics, cell biology, biochemistry and bioinformatics. She has co-authored 12 publications on some top-tier journals. Dr. Ma has been active in SABPA since 2011 and served as the secretary in several committees of SABPA. She has been awarded SABPA Achievement Award for 2012 and 2013.Dr. Ma earned her MS in Genetics from Nankai University and received her Ph.D. degree in Biomedical Sciences from University of Edinburgh, UK in 2011. [Back to top]

Back to Event Page

Register

Date: June 13th, 2015, 8:00am – 5:00pm

Location: Hilton, San Diego/Del Mar

Registration: https://www.123signup.com/event?id=pgqsh

$30 for online registration, $50 for onsite registration, students and postdocs $10 off (The fees include parking at the hotel, program brochure, continental breakfast, coffee break, and lunch). Online registration closes at noon on June 12th.

Organizer: Sino-American Biotechnology & Pharmaceutical Professional Association (SABPA)

Co-Organizer: Elsevier

To create a platform for the entrepreneurs and VCs to mingle,  a dinner reception (2015 San Diego Bio-Pharma Conference Reception or 生物医药年会招待晚宴) will be held after the 14th San Diego Bio-Pharma Conference at Hilton, San Diego/Del Mar. The reception will be by-invitation-only. To secure an invitation, scientists, entrepreneurs, and other professionals who have projects and ideas please submit a half-page project summary to cc_sabpa@yahoo.com.

Direction

Hilton San Diego/Del Mar

15575 Jimmy Durante Blvd

Del Mar, CA 92014

Untitled

Sponsor

  • Platinum Sponsor

Ningbo Ninghai

  • Gold Sponsors

  • Silver Sponsors

  • Bronze Spnsors

Contact

Mail SABPA, San Diego
PO Box. 927631,
San Diego, CA 92192-7631
U.S.A.
Donations
(include sponsor payment)


Sponsorship Information Please click herefor the details.
Membership member@sabpa.org
Information info4@sabpa.org
Webmaster webmaster@sabpa.org

 

Previous